Cancer’s Newest Treatments | Early Detection, Early Treatment, Rapid Therapeutic Development

The idea that diseases are more readily treated when diagnosed at an early stage and when highly disease-specific treatments are deployed is not new. However, it is only in the past few years that the technologies that enable the clinical adoption of this paradigm have emerged as a potential reality. This panel will describe how this can be approached today in diseases as serious as cancer using a cross-discipline model that leverages technologies and care paths that have only recently transitioned from visionary to reality.

Moderator

Keith Flaherty, MD

Director of Clinical Research, Mass General Cancer Center;

Professor of Medicine, HMS

Speakers

Liron Bar-Peled, PhD,

Rullo Family Endowed Chair for Cancer Research, Massachusetts General Hospital;

Associate Professor of Medicine, Harvard Medical School

Michael Mihm, PhD,

Asset Lead, Astellas Pharma

Vincent Miller, MD,

Life Sciences and Drug Development;

Senior Strategic Advisor, LiquidCellDx;

Executive Chairman, Board of Directors, One Biosciences

Aparna Parikh, MD,

Program Director, Colorectal Cancer and Global Cancer Care, Mass General Brigham;

Chief Scientist and Co-Founder at Reversing Early Recurrence (RER);

Associate Professor of Medicine, Harvard Medical School